Cytokine armored CAR T cells for cancer immunotherapy

Immunology and Cell Biology 2026

View at publisher
Authors: Kevin Sek, Kah Min Yap, Woon Xuan Hong, Phillip K. Darcy
DOI: 10.1111/imcb.70112
Cited by: 3
References: 19

Abstract

Cytokine armoring of CAR T cells for enhancing the immunotherapy of cancer. Reprogramming of CAR T-cell phenotypes through (a) IL-158 or (b) IL-9Rα9 engineering. Reprogramming of the tumor microenvironment and recruitment of host antitumor immunity through (c) IL-36γ10 or (d) IL-1211,12 engineering. (e) Tumor-inducible cytokine expression utilizing synthetic NFAT or endogenous NR4A2 promoter systems to restrict systemic expression of potent cytokines for improved safety.

Fields of Study & Subjects

CAR-T cell therapy research Immunotherapy and Immune Responses Virus-based gene therapy research

Publication details

Journal / source
Immunology and Cell Biology
Publisher
Wiley
Volume
104
Issue
5
Pages
485–489
Publication date
5 April 2026
Language
EN